As the federal government implements quality initiative programs this year, brands can either be an integral part in assisting providers or be left to generic solutions. Understand federal quality programs and how they can affect pharmaceutical brands.

Meaningful Use II requires that providers educate the patients at point-of-care. Pharma can support provider needs and integrate within this channel by supplementing patient education with patient portals. Understand strategies that leverage:

• Patient portals as direct-to-consumer engagement
• Patient education requirements for the provider to meet Meaningful Use II

Bring the patient into the conversation to make effective treatment choices:

• Integrate decision support to provide better treatment outcomes
• Enhance patient access by improving support around ongoing care processes
• Navigate systems that incorporate care guidelines

• Strategies to sustain timely and pertinent formulary information at the point-of-care
• Checks and balances for formulary information and support
• Ensure accurate and timely data for evidence-based efficiency and FDA approvals
• Push out data mining for outcomes and population data

Get ahead of the game by offering provider support in preparation for Meaningful Use III:

• Help providers deliver fully functional standards of care that they can push out to the patient
• Coordinate supplemental wrap-around services: Nutrition tips, FAQs, care-giver information, coupons, etc.

With arising standards, pharmaceutical companies could largely benefit from a coordinated and concerted effort to pave the way for a cohesive strategy. Assess opportunities for collaboration, and then connect with peers for a deeper discussion on beneficial positioning for quality initiatives and clinical decision support. Areas to be discussed include:

• Insights into partnerable areas
• ePrescribing
• EHR coordination

Day 1 »